Rhode Island Hospital

Rhode Island Hospital, a division of Lifespan Corporation and an affiliate of Brown University, acts as a prime recipient and prime contractor for federal grants and clinical service contracts delivered to the Department of Veterans Affairs, National Institutes of Health, and other HHS agencies, with 66% of recent awards in prime roles and 34% as a subcontractor or sub-recipient. The hospital does not hold federal procurement contract vehicles as a prime awardee.

Rhode Island Hospital's federal footprint centers on clinical research, specialized pathology services, and health services research. As a prime, the hospital delivers clinical laboratory testing and anatomic pathology consultation services to the VA—a $278.8 thousand BPA with VISN 1 (awarded December 2025, completion November 2030) for statistical and non-statistical testing, muscle and nerve biopsies, and dermatopathology consultation—alongside a portfolio of clinical trial coordination, biomedical research, and implementation science grants from NIH institutes. Representative recent prime grants include a $1.73 million NIAID award (September 2025) for a randomized controlled trial evaluating praziquantel treatment frequency for schistosomiasis-related hepatic fibrosis in Uganda, a $1.59 million NIMH award (August 2025) for research improving depression treatment in youth with HIV, and a $1.3 million NHLBI award (August 2025) for basic and translational research on mitochondrial reactive oxygen species in coronary endothelial cells. The hospital also serves as sub-recipient on grants with Brown University, Johns Hopkins University, University of Pennsylvania, Emory University, and other research partners, with approximately 102 active sub-recipient roles spanning clinical trials, implementation research, biomarker development, and health services research across NIH institutes and CDC programs.

Customer concentration reflects the hospital's research mission. The top customer by award count is the National Institutes of Health (167 awards, $91 thousand combined potential value), with substantial NIH sub-institute activity through the National Heart Lung and Blood Institute (62 awards), National Institute on Drug Abuse (54 awards), National Institute of Mental Health (47 awards), and the Office of the Director (42 awards). By potential value, the Department of Veterans Affairs Veterans Integrated Service Network 1 anchors $2.1 million across 24 awards, reflecting ongoing pathology and research service contracts. Combined, the top five customers represent 48% of recent awards and 78% of potential value. The award portfolio spans 53 distinct federal customer agencies and carries substantial obligated dollars ($945.7 million) relative to potential value ($3.5 million), indicating a mature portfolio of active, funded grants.

Activity has grown significantly—46 awards in 2022 to 120 in 2024, with 102 awards in 2025 and 39 year-to-date in 2026. Fifty-nine awards (combined potential value $279 thousand) face ultimate completion within the next twenty-four months, representing recompete exposure across NIH and VA grant portfolio.

SCI-reported service contract activity is minimal in the source data (2 records, 4.4 FTEs in FY2024), reflecting that Rhode Island Hospital's federal footprint is dominated by research grants and clinical service task orders—categories outside the SCI reporting threshold or scope. The hospital operates as a clinical research institution deeply integrated with Brown University's research enterprise, with sub-awards flowing to and from Brown as the primary research partner. Sub-contractor relationships include work for Leidos (clinical support services), Sanofi Vaccines (nursing home public health surveillance), and Trustees of Boston University (CARB-X rapid pathogen diagnostics research). The hospital does not sit on any named GWAC, BPA, or government-wide IDIQ as a prime; instead, it operates as an eligible provider and research recipient under VA VISN BPAs and NIH grant programs.

The award portfolio shows Rhode Island Hospital as a major academic medical center and research institution with particular strengths in infectious disease research (parasitic infections, schistosomiasis, hepatitis, HIV), cardiovascular research and heart failure mechanisms, substance use disorder treatment and prevention, mental health and behavioral health services research, and pediatric trauma and injury prevention. The hospital's research workforce, clinical laboratory capacity, and affiliation with Brown University position it as a credible research partner for NIH and VA, with federal revenue concentrated in grant administration and clinical trial execution rather than in product delivery or service contracting in traditional GSA or defense procurement vehicles.